Acurion, a precision oncology technology company advancing AI-driven cancer biomarker detection through its OncoGaze™ platform, today announced the closing of its oversubscribed seed financing round, raising $4.3 million against a $4 million target.
The round was led by TK & Partners, with participation from Mesa Verde Venture Partners, The National Foundation for Cancer Research and the Asian Fund for Cancer Research, Bootstrap Ventures, and institutional investors, impact funds, and healthcare executives.
Read More – OpenAI COO Brad Lightcap Steps Down; Fidji Simo Takes Medical Leave
The financing will further support clinical validation, platform development, regulatory preparation, and commercialization as Acurion advances OncoGaze™ toward broader clinical and research adoption.
“This financing represents strong validation of our technology and mission,” said Rick Fultz, CEO of Acurion. “The future of precision oncology depends on making advanced biomarker detection accessible, scalable, and instantly actionable in real-world clinical settings. This investment helps us accelerate development and bring our technology closer to meaningful impact for cancer patients.”
“Acurion stood out immediately — tackling a global problem with a strong technical edge, a standout team, and a clear approach to execution,” said TK & Partners’ Chairman, Tomas Koch.
“AI has the potential to reshape how we detect and act on cancer biomarkers,” said Carey Ng, Ph.D., Managing Partner at Mesa Verde Venture Partners. “What stood out to us about Acurion is their ability to translate complex science into a solution that fits directly into existing clinical workflows. This is the kind of innovation that can expand access to precision oncology at scale.”
Acurion’s technology builds on foundational work by co-founder and Chief Scientific Officer Ludmil Alexandrov, Ph.D., Professor of Cellular and Molecular Medicine at UC San Diego, whose work on mutational signatures has reshaped understanding of cancer origins and treatment response.
The company has achieved significant scientific and industry milestones, including publications in leading oncology and scientific journals, expanding collaborations with clinical partners, and engaging industry leaders.
“We’re moving quickly from validation to deployment,” Fultz added. “Our focus now is executing key clinical and regulatory milestones and getting this into the hands of physicians who can use it.”
Read More – OpenAI acquires TBPN
